Jabil (JBL) is under fresh regulatory scrutiny after the FDA issued a detailed warning letter citing significant Current Good Manufacturing Practice violations at its Pharmaceutics International sterile injectables facility.
At a share price of US$318.08, Jabil has seen a sharp 5.05% 1 day share price return and a 2.42% 7 day share price return, even though the 30 day share price return is down 13.13% and the 90 day share price return is down 17.34%. Total shareholder return of 32.32% year to date and 48.77% over one year signals momentum built over a longer stretch that now meets fresh regulatory risk from the FDA warning letter.
Spot fresh regulatory risk at Jabil, then compare it with a hand picked group of resilient quality plays in our 11 resilient stocks with low risk scores.The FDA warning has coincided with a strong multiyear run in Jabil shares, creating a clear tension. Are you looking at a business reset or simply sentiment resetting the price, and how does that appear in the valuation work that follows?
Most Popular Narrative: 26% Undervalued
The most followed narrative on Jabil pegs fair value near $430 per share, which sits well above the recent $318.08 close and frames the FDA warning against a still-optimistic earnings roadmap.
Strong demand in AI-related markets, with expected revenue growth of 40% year-on-year, indicates significant potential to drive future revenue and improve operating margins through an expanded share of high-growth technology sectors.
Read the complete narrative. Read the complete narrative.
Want to see why that projected future profit pool supports a higher valuation for Jabil? The core of this story is rapid top line expansion, thicker margins, and a future earnings multiple that assumes the AI build out and manufacturing footprint work together. Curious which specific growth and profitability paths need to line up for that fair value to hold?
Result: Fair Value of $429.56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Jabil’s story can break if FDA findings force costly fixes at Pharmaceutics International, or if weakness in EV and renewable energy customers lingers longer than analysts assume.
Find out about the key risks to this Jabil narrative.
Another View on Jabil’s Valuation
The narrative work suggests Jabil might be undervalued around $318, yet the P/E picture looks less forgiving. The stock trades on 38.7x earnings versus 28.6x for the broader US Electronic group and a fair ratio of 40.1x. That leaves only a narrow valuation cushion if sentiment cools.
To see how those earnings multiples compare with the rest of the market and what that gap could mean for future risk or opportunity, take a look at the detailed valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Feeling conflicted by Jabil’s mix of regulatory worries and long term optimism around AI and earnings power? Move quickly, review the numbers yourself, and weigh both sides in the 4 key rewards and 1 important warning sign.
Looking for more Jabil style investment ideas?
If Jabil has sharpened your focus on risk, return, and valuation, do not stop here. Broaden your watchlist with ideas that match your own playbook.
- Target resilient potential bargains that pair quality fundamentals with pricing that still looks reasonable through the 31 high quality undervalued stocks.
- Build a cash flow engine by zeroing in on income ideas in the 6 dividend fortresses that focus on higher yielding payouts.
- Tighten your downside protection by filtering for financially robust candidates in the list of solid balance sheet and fundamentals (23 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com